Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
WALTHAM, Mass., April 27, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2017 on Thursday, May 4, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 2971783. A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
